Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study

• DOI: 10.2337/dc16-1738
• Publication Date: 2017-01-18T02:10:51Z
• Authors: Muhammad Abdul-Ghani; Osama Migahid; Ayman Megahed; John Adams; Curtis Triplitt; Ralph A. DeFronzo; Mahmoud Zirie; Amin Jayyousi
• Keywords: Pioglitazone; Sulfonylurea; Combination therapy

OBJECTIVE The Qatar Study was designed to examine the efficacy of combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin a sulfonylurea. RESEARCH DESIGN AND METHODS study randomized 231 (HbA1c >7.5%, 58 mmol/mol) T2DM sulfonylurea receive 1) weekly (combination therapy) or 2) basal prandial (insulin maintain HbA1c <7.0% (53 mmol/mol). RESULTS After mean follow-up 12 months, caused robust decrease from 10.0 ± 0.6% (86 5.2 at baseline 6.1 0.1% (43 0.7 compared 7.1 (54 0.8 subjects receiving therapy. Combination effective lowering independent sex, ethnicity, BMI, HbA1c. Subjects group experienced significantly greater weight gain and threefold higher rate hypoglycemia than group. CONCLUSIONS exenatide/pioglitazone is very safe therapeutic option